

Contents

Part I Pulmonary Hypertension: Conceptual Bases of the Disease

Definition and Classification of Pulmonary Hypertension	3
Marc Humbert, David Montani, Oleg V. Evgenov, and Gérald Simonneau	
Pulmonary Hypertension: Pathophysiology and Signaling Pathways . . .	31
Bradley A. Maron and Joseph Loscalzo	
Pulmonary Hypertension: Pathology	59
Peter Dorfmueller	
Pulmonary Hypertension: Biomarkers	77
Christopher J. Rhodes, John Wharton, and Martin R. Wilkins	
Rodent Models of Group 1 Pulmonary Hypertension	105
John J. Ryan, Glenn Marsboom, and Stephen L. Archer	

Part II Pulmonary Hypertension: Established Therapies

General Supportive Care	153
Ioana R. Preston	
Calcium-Channel Blockers in Pulmonary Arterial Hypertension	161
Marie-Camille Chaumais, Elise Artaud Macari, and Olivier Sitbon	
Prostacyclins	177
Horst Olschewski	
Endothelin Receptor Antagonists	199
Martine Clozel, Alessandro Maresta, and Marc Humbert	
Phosphodiesterase-5 Inhibitors	229
Barbara A. Cockrill and Aaron B. Waxman	

Inhaled Nitric Oxide for the Treatment of Pulmonary Arterial Hypertension	257
Steven H. Abman	
Part III Pulmonary Hypertension: Novel Pathways and Emerging Therapies	
Soluble Guanylate Cyclase Stimulators in Pulmonary Hypertension	279
Johannes-Peter Stasch and Oleg V. Evgenov	
Therapeutics Targeting of Dysregulated Redox Equilibrium and Endothelial Dysfunction	315
Michael G. Risbano and Mark T. Gladwin	
Rho-Kinase Inhibitors	351
Yoshihiro Fukumoto and Hiroaki Shimokawa	
Serotonin Transporter and Serotonin Receptors	365
Serge Adnot, Amal Houssaini, Shariq Abid, Elisabeth Marcos, and Valérie Amsellem	
Targeting of Platelet-Derived Growth Factor Signaling in Pulmonary Arterial Hypertension	381
Eva Berghausen, Henrik ten Freyhaus, and Stephan Rosenkranz	
Emerging Molecular Targets for Anti-proliferative Strategies in Pulmonary Arterial Hypertension	409
Ly Tu and Christophe Guignabert	
Anti-inflammatory and Immunosuppressive Agents in PAH	437
Jolyane Meloche, Sébastien Renard, Steeve Provencher, and Sébastien Bonnet	
Vasoactive Peptides and the Pathogenesis of Pulmonary Hypertension: Role and Potential Therapeutic Application	477
Reshma S. Baliga, Raymond J. MacAllister, and Adrian J. Hobbs	
Pulmonary Hypertension: Novel Pathways and Emerging Therapies Inhibitors of cGMP and cAMP Metabolism	513
Yassine Sassi and Jean-Sébastien Hulot	
Pulmonary Hypertension: Old Targets Revisited (Statins, PPARs, Beta-Blockers)	531
Geoffrey Watson, Eduardo Oliver, Lan Zhao, and Martin R. Wilkins	

Part IV Conclusions and Outlook

**Pulmonary Hypertension: Current Management
and Future Directions** 551
Lewis J. Rubin

Index 557

Pharmacotherapy of Pulmonary Hypertension

Humbert, M.; Evgenov, O.V.; Stasch, J.-P. (Eds.)

2013, IX, 576 p. 66 illus., 56 illus. in color., Hardcover

ISBN: 978-3-642-38663-3